Harnessing Listeria monocytogenes to target tumors

Claudia Gravekamp, Yvonne Paterson

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Because of its cytosolic localization, Listeria monocytogenes (LM) has long been considered an attractive tool for delivering tumor-associated antigens (TAA) antigens in vivo to combat cancer. LM directly infects antigen-presenting cells (APC) such as monocytes, macrophages and dendritic cells (DC), thereby delivering the TAA into their cytoplasm, resulting in processing and presentation of the antigen to the immune system. This activates adaptive and innate immune responses to the TAA, mediating tumor cell cytolysis. Recently we discovered additional pathways by which Listeria can be harnessed to induce tumor cell death, which suggest new directions in the development of vaccines or therapies against cancer. In one approach, we have used Listeria to induce immune responses that destroy tumor vasculature. Another new pathway involves selective infection of cancer cells with Listeria, followed by tumor cell death through the production of high levels of reactive oxygen species (ROS) and through Listeria-specific cytotoxic T lymphocytes (CTL). This review will focus on the most recent studies on the multiple pathways of LM and how they can be harnessed in the battle against cancer.

Original languageEnglish (US)
Pages (from-to)257-265
Number of pages9
JournalCancer Biology and Therapy
Volume9
Issue number4
StatePublished - Feb 15 2010

Fingerprint

Listeria monocytogenes
Listeria
Neoplasms
Neoplasm Antigens
Antigen Presentation
Cell Death
Active Immunotherapy
Cytotoxic T-Lymphocytes
Adaptive Immunity
Antigen-Presenting Cells
Innate Immunity
Dendritic Cells
Monocytes
Immune System
Reactive Oxygen Species
Cytoplasm
Macrophages
Antigens
Infection

Keywords

  • Angiogenesis
  • Cancer vaccine
  • Immune suppression
  • Immunotherapy
  • Listeria monocytogenes
  • Lysteriolysin O
  • Metastases
  • NADPH oxidase
  • ROS

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Harnessing Listeria monocytogenes to target tumors. / Gravekamp, Claudia; Paterson, Yvonne.

In: Cancer Biology and Therapy, Vol. 9, No. 4, 15.02.2010, p. 257-265.

Research output: Contribution to journalArticle

Gravekamp, Claudia ; Paterson, Yvonne. / Harnessing Listeria monocytogenes to target tumors. In: Cancer Biology and Therapy. 2010 ; Vol. 9, No. 4. pp. 257-265.
@article{9c1eb5932702406c83caa796afcf2abd,
title = "Harnessing Listeria monocytogenes to target tumors",
abstract = "Because of its cytosolic localization, Listeria monocytogenes (LM) has long been considered an attractive tool for delivering tumor-associated antigens (TAA) antigens in vivo to combat cancer. LM directly infects antigen-presenting cells (APC) such as monocytes, macrophages and dendritic cells (DC), thereby delivering the TAA into their cytoplasm, resulting in processing and presentation of the antigen to the immune system. This activates adaptive and innate immune responses to the TAA, mediating tumor cell cytolysis. Recently we discovered additional pathways by which Listeria can be harnessed to induce tumor cell death, which suggest new directions in the development of vaccines or therapies against cancer. In one approach, we have used Listeria to induce immune responses that destroy tumor vasculature. Another new pathway involves selective infection of cancer cells with Listeria, followed by tumor cell death through the production of high levels of reactive oxygen species (ROS) and through Listeria-specific cytotoxic T lymphocytes (CTL). This review will focus on the most recent studies on the multiple pathways of LM and how they can be harnessed in the battle against cancer.",
keywords = "Angiogenesis, Cancer vaccine, Immune suppression, Immunotherapy, Listeria monocytogenes, Lysteriolysin O, Metastases, NADPH oxidase, ROS",
author = "Claudia Gravekamp and Yvonne Paterson",
year = "2010",
month = "2",
day = "15",
language = "English (US)",
volume = "9",
pages = "257--265",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "4",

}

TY - JOUR

T1 - Harnessing Listeria monocytogenes to target tumors

AU - Gravekamp, Claudia

AU - Paterson, Yvonne

PY - 2010/2/15

Y1 - 2010/2/15

N2 - Because of its cytosolic localization, Listeria monocytogenes (LM) has long been considered an attractive tool for delivering tumor-associated antigens (TAA) antigens in vivo to combat cancer. LM directly infects antigen-presenting cells (APC) such as monocytes, macrophages and dendritic cells (DC), thereby delivering the TAA into their cytoplasm, resulting in processing and presentation of the antigen to the immune system. This activates adaptive and innate immune responses to the TAA, mediating tumor cell cytolysis. Recently we discovered additional pathways by which Listeria can be harnessed to induce tumor cell death, which suggest new directions in the development of vaccines or therapies against cancer. In one approach, we have used Listeria to induce immune responses that destroy tumor vasculature. Another new pathway involves selective infection of cancer cells with Listeria, followed by tumor cell death through the production of high levels of reactive oxygen species (ROS) and through Listeria-specific cytotoxic T lymphocytes (CTL). This review will focus on the most recent studies on the multiple pathways of LM and how they can be harnessed in the battle against cancer.

AB - Because of its cytosolic localization, Listeria monocytogenes (LM) has long been considered an attractive tool for delivering tumor-associated antigens (TAA) antigens in vivo to combat cancer. LM directly infects antigen-presenting cells (APC) such as monocytes, macrophages and dendritic cells (DC), thereby delivering the TAA into their cytoplasm, resulting in processing and presentation of the antigen to the immune system. This activates adaptive and innate immune responses to the TAA, mediating tumor cell cytolysis. Recently we discovered additional pathways by which Listeria can be harnessed to induce tumor cell death, which suggest new directions in the development of vaccines or therapies against cancer. In one approach, we have used Listeria to induce immune responses that destroy tumor vasculature. Another new pathway involves selective infection of cancer cells with Listeria, followed by tumor cell death through the production of high levels of reactive oxygen species (ROS) and through Listeria-specific cytotoxic T lymphocytes (CTL). This review will focus on the most recent studies on the multiple pathways of LM and how they can be harnessed in the battle against cancer.

KW - Angiogenesis

KW - Cancer vaccine

KW - Immune suppression

KW - Immunotherapy

KW - Listeria monocytogenes

KW - Lysteriolysin O

KW - Metastases

KW - NADPH oxidase

KW - ROS

UR - http://www.scopus.com/inward/record.url?scp=77953607030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953607030&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 257

EP - 265

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 4

ER -